• Alias: MK-3475, SCH 900475
    • A humanized monoclonal Ig G4 antibody directed against human cell surface receptor PD-1, an inhibitory signaling receptor expressed on surface of activated T- cells. This results in the activation of T-cell-mediated immune responses against tumor cells.
    • FDA approved for recurrent or metastatic SCCHN, adult and pediatric patients with relapsed or refractory Hodgkin lymphoma, unresectable or metastatic melanoma, unresectable or metastatic MSI-high cancers, metastatic NSCLC with PD-L1 expression, or locally advanced or metastatic urothelial carcinoma.
    • Recommended dose: 200 mg IV every 3 weeks
    • Off-label dosing: 2 mg/kg IV weeks (advanced Merkel cell or metastatic melanoma)
    Other topics in Targeted and Immunotherapy Agents